Company Filing History:
Years Active: 1993-1998
Title: Thomas J. Kjeldsen: Innovator in Monoclonal Antibodies and Vaccine Development
Introduction
Thomas J. Kjeldsen is a prominent inventor based in Seattle, WA (US), known for his significant contributions to the field of monoclonal antibodies and vaccine development. With a total of 3 patents, he has made strides in creating methods that target human cancer-associated mucin-type glycoprotein antigens.
Latest Patents
Kjeldsen's latest patents focus on innovative methods for producing monoclonal antibodies and developing vaccines aimed at preventing the growth and replication of cancer cells. One of his notable patents describes a method that involves immunizing a host with a core structure of a mucin-type glycoprotein, followed by the fusion of splenocytes with myeloma cells to create hybridoma cells. This process allows for the selection and cloning of hybridoma cells that secrete antibodies binding to the mucin-type glycoprotein. Additionally, he has developed a vaccine that comprises a purified mucin-type glycoprotein or its synthetic carbohydrate determinant conjugated to a carrier peptide, aimed at treating cancer cells expressing this core structure.
Career Highlights
Kjeldsen is currently associated with The Biomembrane Institute, where he continues to advance research in immunology and cancer treatment. His work has been instrumental in developing methods of passive and active immunization using monoclonal antibodies, which have the potential to significantly impact cancer therapies.
Collaborations
Throughout his career, Kjeldsen has collaborated with notable colleagues such as Henrik Clausen and Anil Singhal, contributing to a rich environment of innovation and research in the field of biotechnology.
Conclusion
Thomas J. Kjeldsen's work in monoclonal antibodies and vaccine development showcases his dedication to advancing medical science and improving cancer treatment options. His innovative methods and collaborative efforts continue to pave the way for future breakthroughs in immunotherapy.